Celerion has a proven track-record in successfully evaluating potential reduced exposure tobacco products that can be applied to our clients’ programs of clinical studies. Our experience working within the evolving tobacco regulatory landscape, allows us to assist our clients, for different regulatory requirements or submission authorities.
The value Celerion provides to clients’ tobacco product clinical studies starts with highly skilled scientists who partner with our clients to plan the events and endpoints to be evaluated. Our scientists are also responsible for planning and performing the statistical analyses, interpreting the data, and providing the written report describing the results. This full service approach enables continuity within a study and allows information to be carried forward into the next study in the program, thereby saving our clients’ time and cost.
Celerion’s extensive experience with endpoints commonly evaluated in tobacco studies and streamlined procedures allow for a rapid turn-around of data and reports.
Our scientists constantly monitor industry trends and pertinent regulations as well as attend key scientific conferences to enable the scientific objectives of our clients’ studies meet regulatory requirements.